Invention Grant
- Patent Title: T-cell reactivity platform
-
Application No.: US16061611Application Date: 2016-12-15
-
Publication No.: US11360079B2Publication Date: 2022-06-14
- Inventor: Hans Grönlund
- Applicant: NEOGAP Therapeutics AB
- Applicant Address: SE Stockholm
- Assignee: NEOGAP Therapeutics AB
- Current Assignee: NEOGAP Therapeutics AB
- Current Assignee Address: SE Stockholm
- Agency: Fish & Richardson P.C.
- Priority: EP15200619 20151216,SE1650493-8 20160412
- International Application: PCT/EP2016/081141 WO 20161215
- International Announcement: WO2017/102921 WO 20170622
- Main IPC: G01N33/50
- IPC: G01N33/50 ; G01N33/564 ; C12N5/0783

Abstract:
Methods for assaying antigen-specific T-cell activation in vitro, comprising the steps of (a) providing a phagocytable particle, having a candidate antigen polypeptide tightly associated thereto, wherein the particle with the associated polypeptide has been subjected to a denaturing wash resulting in an endotoxin level low enough to not interfere with the subsequent steps; (b) providing a viable antigen-presenting cell; (c) contacting the washed particle with the antigen-presenting cell under conditions allowing phagocytosis of the particle by the antigen-presenting cell; (d) providing a T-cell sample to be assayed comprising viable T-cells; (e) contacting the T-cell sample with the antigen-presenting cell contacted with the particle under conditions allowing specific activation of T-cells in response to an antigen presented by an antigen-presenting cell; and (f) determining the degree of T-cell activation in the T-cell sample.
Public/Granted literature
- US20200309764A1 T-CELL REACTIVITY PLATFORM Public/Granted day:2020-10-01
Information query
IPC分类: